MBBS (Hons), FCICM, FRACP, PGDipEcho Claire is a senior intensive care specialist, and became Director of ICU in 2020. Originally from Tasmania, Claire completed her medical degree in Hobart in 1999. After training at both The Alfred and Barwon Health, Claire began work as a Specialist in Barwon Health ICU in 2009. Major clinical projects include developing the Paediatric ICU program in University Hospital Geelong. Her work in this area was a significant factor in UHG being awarded the Victorian Premier’s Health Care Secretary Award for Improving Patient Outcomes and Patient Experience in 2014. Claire has a strong interest in education, having involvement with Deakin University, and ICU Supervisor of Training. Claire is also involved in Quality and Safety activities and is current Chair of the Blood and Blood Products Committee.
Clinical leadership
Claire became Director of Intensive Care at University Hospital Geelong in 2020. She has undertaken the Harvard Emerging Women Executives in Health Care Program, and is Chair of the Barwon Health Blood and Blood Products Committee, and led the development of the Barwon Health Paediatric Critical Care Program from 2011-2018.
Latest news:
-
Thursday, April 8, 2021 - 16:13
JAMA BACLOREA High-dose baclofen reduced agitation-related events in adult patients with unhealthy alcohol use requiring mechanical ventilation. However secondary outcomes of deeper sedation, longer duration of mechanical ventilation, prolonged ICU care = more research
Tuesday, April 6, 2021 - 14:25JAMA Mechanical ventilation weaning practices vary internationally, regard to the use of protocols, screening for and conducting SBTs, adjustment of ventilator support, and the responsibility of clinicians involved in weaning
Tuesday, April 6, 2021 - 12:01JAMA HENIVOT Trial -Helmet NIV vs HFNC for critically ill patients with mod-severe hypoxemic COVID resp failure = no diff in the resp support fee days (28 d). Secondary diff in intubation, lower in helmet group, ie overall no difference in 28-d resp support, but helmet lower proportion of this time intubated.
Friday, February 19, 2021 - 07:30JAMA RCT does not support use of single high dose oral vitamin D3 for treatment of moderate to severe COVID-19 in hospitalized patients. Limitations in design, however, confirms lack of benefit reported in multiple large non-COVID trials in hospital or ICU patients (VIOLET, VITdAL-ICU)
Sunday, February 14, 2021 - 09:30NEJM DePPaRT: 1% of patients with loss of cardiac activity after planned withdrawal of life sustaining therapy have transient resumption of cardiac activity observable by bedside reports and corroborated by ECG and IABP waveform activity. Retrospective waveform review showed resumption of cardiac activity in 14% of patients. The longest period of pulselessness that was followed by resumption of cardiac activity was 4 minutes 20 seconds.